Corbus Pharmaceuticals Holdings Inc.

Last updated September 27, 2026

Organization details

Legal name
Corbus Pharmaceuticals Holdings Inc.
Former names
SAV Acquisition Corp
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Norwood
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
CRBP
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001595097
EIN
46-4348039

Board of directors

Chief executives

Yuval Cohen · Chief Executive Officer
Dates unknown

Director election results

Annual meeting of May 13, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

4 of this board's directors also sit on 6 other boards.

Network of Corbus Pharmaceuticals Holdings Inc.'s board connections Akari Therapeutics plc Akari Therapeutics plc Butterfly Network Inc. Butterfly Network Inc. Century Therapeutics Inc. Century Therapeutics I... Immunovant Inc. Immunovant Inc. Janux Therapeutics Inc. Janux Therapeutics Inc... uniQure N.V. uniQure N.V. Brent Pfeiffenberger Brent Pfeiffenberger Peter Salzmann Peter Salzmann Rachelle Suzanne Jacques Rachelle Suzanne Jac... Winston Kung Winston Kung Corbus Pharmaceuticals Hol...
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$126,241
3 purchases by 1 insider
Sold, last 12 months
$1,686,584
17 sales by 9 insiders
Date Insider Transaction Shares Price Value
Sep 14, 2026 Yong Ben Director Open-market sale −2,000 $7.84 $15,683
Aug 16, 2026 Nicacio Leonardo Viana Officer (Chief Medical Officer) Grant or award +58,333 — —
Aug 11, 2026 Saxena Nishant C Officer (Chief Business Officer) Open-market purchase +2,600 $9.63 $25,036
Aug 7, 2026 Yuval Cohen Director, Officer (Chief Executive Officer) Open-market sale −17,000 $10.08 $171,396
Aug 7, 2026 Moran Sean F. Officer (Chief Financial Officer) Open-market sale −12,000 $10.08 $120,971
Jun 10, 2026 Winston Kung Director Open-market sale −2,026 $7.91 $16,026
Jun 10, 2026 John Kenneth Jenkins Director Open-market sale −4,800 $7.91 $37,968
Jun 10, 2026 Anne Altmeyer Director Open-market sale −2,412 $7.91 $19,079
Jun 3, 2026 Saxena Nishant C Officer (Chief Business Officer) Open-market purchase +9,000 $7.58 $68,220
Jun 2, 2026 Saxena Nishant C Officer (Chief Business Officer) Open-market purchase +4,500 $7.33 $32,985
May 21, 2026 Saxena Nishant C Officer (Chief Business Officer) Grant or award +58,300 — —
May 19, 2026 Winston Kung Director Grant or award +3,800 — —
May 19, 2026 Rachelle Suzanne Jacques Director Grant or award +3,800 — —
May 19, 2026 John Kenneth Jenkins Director Grant or award +3,800 — —
May 19, 2026 Anne Altmeyer Director Grant or award +3,800 — —

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.